Zivo Bioscience (ZIVO) Osake Kurssi

Zivo Bioscience, Inc. generates revenue by developing and selling natural bioactive ingredients derived from its proprietary algal strains to manufacturers in the animal, human, dietary supplement, and medical food industries. The company focuses on research and identification of bioactive molecules for use in products targeting autoimmune and inflammatory response modulation. It also develops and sells health optimization tests that help users identify future health risks and personalize their wellness approaches. The firm manufactures algal products and derivatives through its proprietary platforms, serving both human and animal health markets. The company's primary customers include manufacturers of dietary supplements, medical foods, and pharmaceuticals seeking natural ingredients for their formulations. These manufacturers utilize Zivo's bioactive molecules to create products that address autoimmune and inflammatory conditions. Additionally, the company's health optimization tests are marketed to consumers interested in proactive health management, offering personalized insights based on bioactive data. Zivo's product portfolio spans from raw ingredients to finished test kits, all derived from its algal and bacterial host cultures. Zivo Bioscience's revenue streams are built around its proprietary algal strains, which serve as the foundation for all its products. The company's focus on natural compounds and bioactive molecules allows it to target both the supplement and medical food sectors, as well as the emerging market for personalized health diagnostics. By leveraging its research capabilities, Zivo provides specialized ingredients and diagnostic tools that cater to specific health challenges, particularly those related to immune response and inflammation. The firm's business model centers on creating value through scientific innovation in natural product development and health monitoring technologies.